Clinical Trial Update: TAF to Prevent HBV Reactivation in Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating tenofovir alafenamide (TAF) to prevent hepatitis B reactivation in cancer patients; the study is currently active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• TAF (tenofovir alafenamide) (tenofovir alafenamide)

Snippet

Sponsor: Chiayi Christian Hospital | Conditions: Hepatitis B Reactivation | Phase 4 | Status: ACTIVE_NOT_RECRUITING